Adma Biologics, Inc. (ADMA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-03

Key Insights

  • Insider Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance, disposed of 20,362 shares of ADMA Biologics, likely to cover tax withholding requirements upon the vesting of restricted stock units (RSUs).
  • Kestenberg-Messina continues to hold a significant equity stake in ADMA Biologics, including 446,238 shares, as well as unvested RSUs that will vest over the next four years.
  • The reported transaction appears to be a routine stock disposition to cover taxes and does not indicate a broader trend of insider selling, suggesting the insider remains committed to the company's long-term success.
Filing tone (AI): Neutral
View Original Filing →
Current Report Filed: 2026-03-27

Key Insights

  • ADMA Biologics, Inc. issued a press release on March 27, 2026, which could indicate important updates or developments for the company.
  • The filing does not provide any specific details about the content of the press release, so further analysis would be needed to determine the significance of the announcement.
  • Investors should closely monitor any future disclosures from ADMA Biologics to understand the potential impact on the company's financial performance and operations.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-03-09

Key Insights

  • ADMA Biologics insider Steve Elms has purchased a significant amount of the company's common stock in the past two trading days, acquiring a total of 14,000 shares at an average price of $15.53 per share.
  • Elms' purchases represent ongoing confidence in ADMA Biologics' prospects, as he is a director and a representative of major shareholder Aisling Capital, which owns over 2 million shares.
  • The timing of these purchases, just over a month before the end of the fiscal year, could signal that Elms expects positive financial results or other material developments from the company in the near future.
Filing tone (AI): Positive
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • ADMA Biologics reported preliminary unaudited full year 2025 revenue, providing a positive business update for investors.
  • The company plans to present a corporate presentation to potential investors, strategic partners, and industry analysts, which could indicate upcoming growth initiatives.
  • The filing indicates ADMA Biologics is an emerging growth company, which may give it more flexibility in financial reporting and accounting standards.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Adma Biologics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.